Related Experiment Videos
Retrospective cohort study of 148 patients with polyclonal gammopathy
A Dispenzieri1, M A Gertz, T M Therneau
1Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Insights
Moderate to marked polyclonal gammopathy often indicates underlying liver disease, connective tissue disease, infection, or malignancy. Survival depends on age, albumin, disease group, and platelet count.
Area of Science:
- Clinical Medicine
- Immunology
- Hematology
Background:
- Polyclonal gammopathy, characterized by elevated levels of multiple immunoglobulin types, is often associated with various underlying conditions.
- Understanding the clinical correlates and prognostic factors of significant polyclonal gammopathy is crucial for patient management.
Purpose of the Study:
- To quantify the clinical conditions and laboratory values associated with moderate to marked polyclonal gammopathy.
- To identify factors influencing survival in patients with polyclonal gammopathy.
Main Methods:
- Retrospective cohort study of 148 patients with polyclonal gamma globulin levels ≥ 3.0 g/dL.
- Review of patient characteristics, laboratory values, disease states, and survival data.
- Multivariate analysis to determine predictors of survival.
Main Results:
- Liver disease was the most common associated condition (61%), followed by connective tissue diseases (22%) and chronic infections (6%).
- Median follow-up was 67 months, with 63% of patients surviving.
- Age, albumin concentration, disease group, and platelet count were significant predictors of survival.
Conclusions:
- Moderate to marked polyclonal gammopathy frequently reflects underlying conditions such as liver disease, connective tissue disease, infection, or malignancy.
- No patients developed myeloma or clonal disorders, suggesting polyclonal gammopathy is distinct from these conditions.
Objective:
To quantify clinical conditions and laboratory values associated with moderate to marked polyclonal gammopathy.
Patients And Methods:
Patient characteristics, laboratory correlates, evolving disease states, and survival of all patients seen at the Mayo Clinic, Rochester, Minn, during 1991 with a polyclonal gamma globulin level of 3.0 g/dL or higher were reviewed in this retrospective cohort study.
Results:
One hundred forty-eight patients were identified (median age, 58 years; 59% female). In 130 patients (88%), only 1 diagnosis was identified. Liver disease was the most common single disease association in 79 (61%) of 130 patients, followed by connective tissue diseases in 28 (22%), chronic infections in 8 (6%), hematologic disorders in 6 (5%), and nonhematologic malignancies in 4 (3%). No difference in gamma globulin levels existed between groups. With a median follow-up of 67 months, 90 (63%) of 143 patients for whom follow-up was available were alive. By multivariate analysis, age, albumin concentration, disease group, and platelet count were predictive of survival. No patient developed myeloma or a clonal plasmaproliferative disorder.
Conclusion:
Moderate to marked polyclonal gammopathy may reflect an underlying condition: liver disease, connective tissue disease, hematologic disorder, infection, or malignancy.